Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 10, 2014, Pages 1179-1207

  Ruemmele, F M ^a,b,c   Veres, G ^d   Kolho, K L ^e   Griffiths, A ^f   Levine, A ^g   Escher, J C ^h   Amil Dias, J ⁱ   Barabino, A ^j   Braegger, C P ^k   Bronsky, J ^l   Buderus, S ^m   Martin de Carpi J ⁿ   De Ridder, L ^h   Fagerberg, U L ^o   Hugot, J P ^b,p   Kierkus, J ^q   Kolacek, S ^r   Koletzko, S ^s   Lionetti, P ^t   Miele, E ^u   Navas Lopez V M ^v   Paerregaard, A ^w   Russell, R K ^x   Serban, D E ^y   Shaoul, R ^z   Van Rheenen, P ^aa   Veereman, G ^ab   Weiss, B ^ac   Wilson, D ^ad   Dignass, A ^ae   Eliakim, A ^af   Winter, H ^ag   Turner, D ^ac   Baumann, Ulrich ^ah   Koletzko, Bert ^ah   D'Antiga, Lorenzo ^ah   Troncone, Riccardo ^ah   Benninga, Mark ^ah   Mearin, Louisa ^ah   Phillips, Alan ^ah   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c IMAGINE INSTITUTE   (France)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g TEL AVIV UNIVERSITY   (Israel)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ HOSPITAL DE SÃO JOÃO   (Portugal)

^j G GASLINI INSTITUTE   (Italy)

^k UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^m ST MARIEN HOSPITAL   (Germany)

ⁿ HOSPITAL SANT JOAN DE DÉU   (Spain)

^o KAROLINSKA INSTITUTE   (Sweden)

^p HÔPITAL ROBERT DEBRÉ   (France)

^q CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^r Croatia   (Croatia)

^s LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^t UNIVERSITY OF FLORENCE   (Italy)

^u UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^v HOSPITAL MATERNO INFANTIL   (Spain)

^w HVIDOVRE HOSPITAL   (Denmark)

^x ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^y IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^z TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^aa UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ab HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^ac SHEBA MEDICAL CENTER   (Israel)

^ad ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^ae MASSACHUSETTS GENERAL HOSPITAL   (United States)

^af HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^ag AGAPLESION MARKUS KRANKENHAUS   (Germany)

^ah Agaplesion Markus Hospital ^*

more..

Author keywords

Crohn's disease; Guidelines; Medical therapy; Pediatric

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; AZITHROMYCIN; BUDESONIDE; CIPROFLOXACIN; CLOFAZIMINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OMEGA 3 FATTY ACID; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RIFABUTIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; AMINOSALICYLIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILD GROWTH; CHILDHOOD DISEASE; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ENTERIC FEEDING; EXCLUSIVE ENTERAL NUTRITION; FLU LIKE SYNDROME; GASTROENTEROLOGIST; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEALING; HOT FLUSH; HUMAN; HYPOTENSION; HYPOXEMIA; HYPOXIA; INFORMATION DISSEMINATION; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NUTRITIONAL SUPPORT; PANCREATITIS; PATIENT SAFETY; PHARMACEUTICAL CARE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; TREATMENT RESPONSE; VOMITING; ADOLESCENT; ALGORITHM; ANTAGONISTS AND INHIBITORS; MAINTENANCE CHEMOTHERAPY; PRACTICE GUIDELINE; PROCEDURES;

6-MERCAPTOPURINE; ADOLESCENT; ADRENAL CORTEX HORMONES; ALGORITHMS; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CHILD; CROHN DISEASE; ENTERAL NUTRITION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; METHOTREXATE; REMISSION INDUCTION; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908254592     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.04.005     Document Type: Article

References (281)

1. Benchimol E.I., Fortinsky K.J., Gozdyra P., Van den Heuvel M., Van Limbergen J., Griffiths A.M. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011, 17(1):423-439.
2. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., Ollendorf D., Bousvaros A., Grand R.J., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5(12):1424-1429.
3. Polito J.M., Childs B., Mellits E.D., Tokayer A.Z., Harris M.L., Bayless T.M. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996, 111(3):580-586.
4. Griffiths A.M. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004, 18(3):509-523.
5. Van Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., Nimmo E.R., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135(4):1114-1122.
6. Vernier-Massouille G., Balde M., Salleron J., Turck D., Dupas J.L., Mouterde O., et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008, 135(4):1106-1113.
7. Pigneur B., Seksik P., Viola S., Viala J., Beaugerie L., Girardet J.P., et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010, 16(6):953-961.
8. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371(9613):660-667.
9. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61(11):1619-1635.
10. Rismo R., Olsen T., Ciu G., Paulssen E.J., Christiansen I., Florholmen J., et al. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 2012, 47(10):1200-1210.
11. Kierkus J., Dadalski M., Szymanska E., Oracz G., Wegner A., Gorczewska M., et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. Eur J Gastroenterol Hepatol 2012, 24(5):495-500.
12. Laharie D., Reffet A., Belleannee G., Chabrun E., Subtil C., Razaire S., et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011, 33(6):714-721.
13. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138(2):463-468. [quiz e10-1].
14. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011, 17(6):1415-1422.
15. Rimola J., Ordas I., Rodriguez S., Garcia-Bosch O., Aceituno M., Llach J., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17(8):1759-1768.
16. Sipponen T., Karkkainen P., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008, 28(10):1221-1229.
17. Walters T.D., Griffiths A.M. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009, 6(9):513-523.
18. Bailey D.A. The Saskatchewan pediatric bone mineral accrual study: bone mineral acquisition during the growing years. Int J Sports Med 1997, 18(Suppl. 3):S191-S194.
19. Pfefferkorn M., Burke G., Griffiths A., Markowitz J., Rosh J., Mack D., et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009, 48(2):168-174.
20. Escher J.C. Mucosal healing in pediatric Crohn's disease: pro/con balance. Inflamm Bowel Dis 2004, 10(4):484.
21. Bousvaros A. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill?. Inflamm Bowel Dis 2004, 10(4):481-483.
22. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130(3):650-656.
23. Allez M., Lemann M., Bonnet J., Cattan P., Jian R., Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002, 97(4):947-953.
24. Cosnes J., Bourrier A., Nion-Larmurier I., Sokol H., Beaugerie L., Seksik P. Factors affecting outcomes in Crohn's disease over 15years. Gut 2012, 61(8):1140-1145.
25. Levine A., Koletzko S., Turner D., Escher J.C., Cucchiara S., de Ridder L., et al. The ESPGHAN Revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2013, [EPUB of print].
26. Levine A., Griffiths A., Markowitz J., Wilson D.C., Turner D., Russell R.K., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011, 17(6):1314-1321.
27. Zachos M., Tondeur M., Griffiths A.M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007, 1:Cd000542.
28. Heuschkel R.B., Menache C.C., Megerian J.T., Baird A.E. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000, 31(1):8-15.
29. Dziechciarz P., Horvath A., Shamir R., Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007, 26(6):795-806.
30. Thomas A.G., Taylor F., Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993, 17(1):75-81.
31. Sanderson I.R., Udeen S., Davies P.S., Savage M.O., Walker-Smith J.A. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987, 62(2):123-127.
32. Seidman E., Lohoues M.J., Turgeon J., Bouthillier L., Morin C.L. Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long term results. Gastroenterology 1991, 100:A250.
33. Terrin G.C.R., Ambrosini A. A semielemental diet (Pregomin) as pri- mary therapy for inducing remission in children with active Crohn''s disease. Ital J Pediatr 2002, 28:401-405.
34. Seidman E.G.A., Jones A., Issenman R. Semi-elemental (S-E) diet versus prednisone in pediatric Crohn's disease. Gastroenterology 1993. Gastroenterology 1993, 104:A778.
35. Ruuska T., Savilahti E., Maki M., Ormala T., Visakorpi J.K. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 1994, 19(2):175-180.
36. Borrelli O., Cordischi L., Cirulli M., Paganelli M., Labalestra V., Uccini S., et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006, 4(6):744-753.
37. Grogan J.L., Casson D.H., Terry A., Burdge G.C., El-Matary W., Dalzell A.M. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis 2012, 18(2):246-253.
38. Day A.S., Whitten K.E., Sidler M., Lemberg D.A. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008, 27(4):293-307.
39. Wilson D.C., Thomas A.G., Croft N.M., Newby E., Akobeng A.K., Sawczenko A., et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010, 50(Suppl. 1):S14-S34.
40. Teahon K., Pearson M., Smith T., Bjarnason I. Alterations in nutritional status and disease activity during treatment of Crohn's disease with elemental diet. Scand J Gastroenterol 1995, 30(1):54-60.
41. Bannerjee K., Camacho-Hubner C., Babinska K., Dryhurst K.M., Edwards R., Savage M.O., et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004, 38(3):270-275.
42. Buchanan E., Gaunt W.W., Cardigan T., Garrick V., McGrogan P., Russell R.K. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther 2009, 30(5):501-507.
43. Rubio A., Pigneur B., Garnier-Lengline H., Talbotec C., Schmitz J., Canioni D., et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther 2011, 33(12):1332-1339.
44. Johnson T., Macdonald S., Hill S.M., Thomas A., Murphy M.S. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006, 55(3):356-361.
45. Akobeng A.K., Miller V., Stanton J., Elbadri A.M., Thomas A.G. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000, 30(1):78-84.
46. Ludvigsson J.F., Krantz M., Bodin L., Stenhammar L., Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr 2004, 93(3):327-335. [Oslo, Norway: 1992].
47. Verma S., Brown S., Kirkwood B., Giaffer M.H. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000, 95(3):735-739.
48. Rodrigues A.F., Johnson T., Davies P., Murphy M.S. Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease?. Arch Dis Child 2007, 92(9):767-770.
49. Afzal N.A., Van Der Zaag-Loonen H.J., Arnaud-Battandier F., Davies S., Murch S., Derkx B., et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004, 20(2):167-172.
50. Gailhoustet L., Goulet O., Cachin N., Schmitz J. Study of psychological repercussions of 2 modes of treatment of adolescents with Crohn's disease. Arch Pediatr 2002, 9(2):110-116.
51. Critch J., Day A.S., Otley A., King-Moore C., Teitelbaum J.E., Shashidhar H. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012, 54(2):298-305.
52. Whitten K.E., Rogers P., Ooi C.Y., Day A.S. International survey of enteral nutrition protocols used in children with Crohn's disease. J Dig Dis 2012, 13(2):107-112.
53. Fell J.M., Paintin M., Arnaud-Battandier F., Beattie R.M., Hollis A., Kitching P., et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000, 14(3):281-289.
54. Afzal N.A., Davies S., Paintin M., Arnaud-Battandier F., Walker-Smith J.A., Murch S., et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005, 50(8):1471-1475.
55. Knight C., El-Matary W., Spray C., Sandhu B.K. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005, 24(5):775-779.
56. Day A.S., Whitten K.E., Lemberg D.A., Clarkson C., Vitug-Sales M., Jackson R., et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006, 21(10):1609-1614.
57. Berni Canani R., Terrin G., Borrelli O., Romano M.T., Manguso F., Coruzzo A., et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006, 38(6):381-387.
58. Beattie R.M., Schiffrin E.J., Donnet-Hughes A., Huggett A.C., Domizio P., MacDonald T.T., et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994, 8(6):609-615.
59. Cameron F.L., Gerasimidis K., Papangelou A., Missiou D., Garrick V., Cardigan T., et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2013, 37(6):622-629.
60. Turner D., Levine A., Escher J.C., Griffiths A.M., Russell R.K., Dignass A., et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012, 55(3):340-361.
61. Ford A.C., Bernstein C.N., Khan K.J., Abreu M.T., Marshall J.K., Talley N.J., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106(4):590-599. [quiz 600].
62. Escher J.C. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004, 16(1):47-54.
63. Levine A., Weizman Z., Broide E., Shamir R., Shaoul R., Pacht A., et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003, 36(2):248-252.
64. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119(4):895-902.
65. Tung J., Loftus E.V., Freese D.K., El-Youssef M., Zinsmeister A.R., Melton L.J., et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006, 12(12):1093-1100.
66. Sidoroff M., Kolho K.L. Glucocorticoids in pediatric inflammatory bowel disease. Scand J Gastroenterol 2012, 47(7):745-750.
67. Byron M.A., Jackson J., Ansell B.M. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983, 76(6):452-457.
68. Shepherd H.A., Barr G.D., Jewell D.P. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 1986, 8(2):154-159.
69. Sandhu B.K., Fell J.M., Beattie R.M., Mitton S.G., Wilson D.C., Jenkins H. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010, 50(Suppl. 1):S1-S13.
70. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98(4):811-818.
71. Olaison G., Sjodahl R., Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990, 31(3):325-328.
72. Mantzaris G.J., Christidou A., Sfakianakis M., Roussos A., Koilakou S., Petraki K., et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009, 15(3):375-382.
73. Markowitz J., Hyams J., Mack D., Leleiko N., Evans J., Kugathasan S., et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006, 4(9):1124-1129.
74. Kolho K.L., Raivio T., Lindahl H., Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006, 41(6):720-725.
75. Jakobsen C., Munkholm P., Paerregaard A., Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators-a population-based study. Inflamm Bowel Dis 2011, 17(8):1731-1740.
76. Levine A., Broide E., Stein M., Bujanover Y., Weizman Z., Dinari G., et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002, 140(1):75-80.
77. Seow C.H., Benchimol E.I., Griffiths A.M., Otley A.R., Steinhart A.H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 3:Cd000296.
78. Nunes T., Barreiro-de Acosta M., Marin-Jimenez I., Nos P., Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis 2013, 7(3):183-191.
79. De Cassan C., Fiorino G., Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. Dig Dis 2012, 30(4):368-375.
80. Levine A., Kori M., Dinari G., Broide E., Shaoul R., Yerushalmi B., et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009, 15(7):1055-1061.
81. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4(1):28-62.
82. Dilger K., Alberer M., Busch A., Enninger A., Behrens R., Koletzko S., et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther 2006, 23(3):387-396.
83. Huscher D., Thiele K., Gromnica-Ihle E., Hein G., Demary W., Dreher R., et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009, 68(7):1119-1124.
84. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002, 96(1):23-43.
85. Vihinen M.K., Kolho K.L., Janne O.A., Andersson S., Raivio T. Circulating adiponectin as a marker for glucocorticoid-related side effects in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009, 48(4):504-506.
86. Sidoroff M., Kolho K.L. Glucocorticoid sensitivity in inflammatory bowel disease. Ann Med 2012, 44(6):578-587.
87. Thia K.T., Mahadevan U., Feagan B.G., Wong C., Cockeram A., Bitton A., et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009, 15(1):17-24.
88. Khan K.J., Ullman T.A., Ford A.C., Abreu M.T., Abadir A., Marshall J.K., et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106(4):661-673.
89. Bermejo F., Garrido E., Chaparro M., Gordillo J., Manosa M., Algaba A., et al. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough?. Inflamm Bowel Dis 2012, 18(8):1509-1514.
90. Ursing B., Alm T., Barany F., Bergelin I., Ganrot-Norlin K., Hoevels J., et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982, 83(3):550-562.
91. Colombel J.F., Lemann M., Cassagnou M., Bouhnik Y., Duclos B., Dupas J.L., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999, 94(3):674-678.
92. Borgaonkar M.R., MacIntosh D.G., Fardy J.M. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000, 95(3):725-729.
93. Feller M., Huwiler K., Schoepfer A., Shang A., Furrer H., Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010, 50(4):473-480.
94. Levine A., Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis 2011, 5(3):222-226.
95. Muniyappa P., Gulati R., Mohr F., Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009, 49(4):400-404.
96. Barabino A., Torrente F., Ventura A., Cucchiara S., Castro M., Barbera C. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 2002, 16(6):1125-1130.
97. Jaspers G.J., Verkade H.J., Escher J.C., de Ridder L., Taminiau J.A., Rings E.H. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006, 12(9):831-836.
98. Riello L., Talbotec C., Garnier-Lengline H., Pigneur B., Svahn J., Canioni D., et al. Tolerance and efficacy of azathioprine in pediatric Crohn's disease. Inflamm Bowel Dis 2011, 17(10):2138-2143.
99. Punati J., Markowitz J., Lerer T., Hyams J., Kugathasan S., Griffiths A., et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008, 14(7):949-954.
100. Prefontaine E., Sutherland L.R., Macdonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 1:Cd000067.
101. Willoughby J.M., Beckett J., Kumar P.J., Dawson A.M. Controlled trial of azathioprine in Crohn's disease. Lancet 1971, 2(7731):944-947.
102. Rosenberg J.L., Levin B., Wall A.J., Kirsner J.B. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975, 20(8):721-726.
103. O'Donoghue D.P., Dawson A.M., Powell-Tuck J., Bown R.L., Lennard-Jones J.E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978, 2(8097):955-957.
104. Summers R.W., Switz D.M., Sessions J.T., Becktel J.M., Best W.R., Kern F., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77(4 Pt 2):847-869.
105. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37(5):674-678.
106. Lemann M., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128(7):1812-1818.
107. D'Haens G.R., Vermeire S., Van Assche G., Noman M., Aerden I., Van Olmen G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135(4):1123-1129.
108. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127(3):723-729.
109. Ramadas A.V., Gunesh S., Thomas G.A., Williams G.T., Hawthorne A.B. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59(9):1200-1206.
110. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60(7):930-936.
111. Cleynen I., Gonzalez J.R., Figueroa C., Franke A., McGovern D., Bortlik M., et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013, 62(11):1556-1565.
112. Cosnes J., Bourrier A., Laharie D., Nahon S., Bouhnik Y., Carbonnel F., et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013, 145(4):758-765. [e2; quiz e14-5].
113. Panes J., Lopez-Sanroman A., Bermejo F., Garcia-Sanchez V., Esteve M., Torres Y., et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013, 145(4):766-774. [e1].
114. Fuentes D., Torrente F., Keady S., Thirrupathy K., Thomson M.A., Walker-Smith J.A., et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17(7):913-921.
115. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999, 50(5):667-671.
116. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362(15):1383-1395.
117. Gearry R.B., Barclay M.L., Burt M.J., Collett J.A., Chapman B.A. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004, 13(8):563-567.
118. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24(2):331-342.
119. Kirschner B.S. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115(4):813-821.
120. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Price S., et al. Serious infection and mortality in patients with Crohn's disease: more than 5years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107(9):1409-1422.
121. Baldassano R., Colletti R.B., Cucchiara S., Dubinsky M., Escher J.C., Faubion W.A., et al. 41 serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: develop registry data. Gastroenterology 2013, 144(5 Suppl. 1):S-11.
122. Ledder O.D., Lemberg D.A., Ooi C.Y., Day A.S. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?. J Pediatr Gastroenterol Nutr 2013, 57(5):583-586.
123. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122(4):904-915.
124. Ansari A., Hassan C., Duley J., Marinaki A., Shobowale-Bakre E.M., Seed P., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(10):1743-1750.
125. Benkov K., Lu Y., Patel A., Rahhal R., Russell G., Teitelbaum J. Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr 2013, 56(3):333-340.
126. Dubinsky M.C., Reyes E., Ofman J., Chiou C.F., Wade S., Sandborn W.J. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005, 100(10):2239-2247.
127. Priest V.L., Begg E.J., Gardiner S.J., Frampton C.M., Gearry R.B., Barclay M.L., et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006, 24(8):767-781.
128. Winter J., Walker A., Shapiro D., Gaffney D., Spooner R.J., Mills P.R. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(6):593-599.
129. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118(4):705-713.
130. Osterman M.T., Kundu R., Lichtenstein G.R., Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130(4):1047-1053.
131. Rahhal R.M., Bishop W.P. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008, 14(12):1678-1682.
132. Gerich M.E., Quiros J.A., Marcin J.P., Tennyson L., Henthorn M., Prindiville T.P. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis 2010, 4(5):546-552.
133. Shih D.Q., Nguyen M., Zheng L., Ibanez P., Mei L., Kwan L.Y., et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012, 36(5):449-458.
134. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987, 423:169-178.
135. Dervieux T., Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998, 44(3):551-555.
136. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54(8):1121-1125.
137. Camus M., Seksik P., Bourrier A., Nion-Larmurier I., Sokol H., Baumer P., et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013, 11(4):389-394.
138. Ashworth L.A., Billett A., Mitchell P., Nuti F., Siegel C., Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012, 18(5):838-843.
139. Colletti R.B., Cucchiara S., Dubinsky M., Escher J.C., Faubion W.A., Fell J., et al. 833 malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (develop) registry data. Gastroenterology 2013, 144(5, Supplement 1):S-147.
140. Kotlyar D.S., Osterman M.T., Diamond R.H., Porter D., Blonski W.C., Wasik M., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9(1):e1-e41.
141. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., Bouvier A.M., Chevaux J.B., Simon T., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141(5):1621-1628. [e1-5].
142. Singh H., Nugent Z., Demers A.A., Bernstein C.N. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011, 141(5):1612-1620.
143. van Schaik F.D., van Oijen M.G., Smeets H.M., van der Heijden G.J., Siersema P.D., Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012, 61(2):235-240.
144. Turner D., Grossman A.B., Rosh J., Kugathasan S., Gilman A.R., Baldassano R., et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007, 102(12):2804-2812. [quiz 3, 13].
145. Uhlen S., Belbouab R., Narebski K., Goulet O., Schmitz J., Cezard J.P., et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006, 12(11):1053-1057.
146. Boyle B., Mackner L., Ross C., Moses J., Kumar S., Crandall W. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010, 51(6):714-717.
147. Mack D.R., Young R., Kaufman S.S., Ramey L., Vanderhoof J.A. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998, 132(5):830-835.
148. Ravikumara M., Hinsberger A., Spray C.H. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007, 44(4):427-430.
149. Weiss B., Lerner A., Shapiro R., Broide E., Levine A., Fradkin A., et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009, 48(5):526-530.
150. Willot S., Noble A., Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis 2011, 17(12):2521-2526.
151. Alfadhli A.A., McDonald J.W., Feagan B.G. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005, 1:Cd003459.
152. Patel V., Macdonald J.K., McDonald J.W., Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 4:Cd006884.
153. Nathan D.M., Iser J.H., Gibson P.R. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008, 23(6):954-958.
154. Hashkes P.J., Becker M.L., Cabral D.A., Laxer R.M., Paller A.S., Rabinovich C.E., et al. Methotrexate: new uses for an old drug. J Pediatr 2014, 164:231-236.
155. Kempinska A., Benchimol E.I., Mack A., Barkey J., Boland M., Mack D.R. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr 2011, 53(4):389-393.
156. Valentino P.L., Church P.C., Shah P.S., Beyene J., Griffiths A.M., Feldman B.M., et al. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014, 20:47-59.
157. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132(3):863-873. [quiz 1165-6].
158. Ruemmele F.M., Lachaux A., Cezard J.P., Morali A., Maurage C., Ginies J.L., et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009, 15(3):388-394.
159. Hyams J.S., Markowitz J., Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000, 137(2):192-196.
160. Kugathasan S., Werlin S.L., Martinez A., Rivera M.T., Heikenen J.B., Binion D.G. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000, 95(11):3189-3194.
161. Baldassano R., Braegger C.P., Escher J.C., DeWoody K., Hendricks D.F., Keenan G.F., et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003, 98(4):833-838.
162. Cezard J.P., Nouaili N., Talbotec C., Hugot J.P., Gobert J.G., Schmitz J., et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003, 36(5):632-636.
163. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., De Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18(4):425-431.
164. Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004, 36(5):342-347.
165. Afzal N.A., Ozzard A., Keady S., Thomson M., Murch S., Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci 2007, 52(12):3329-3333.
166. Wynands J., Belbouab R., Candon S., Talbotec C., Mougenot J.F., Chatenoud L., et al. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr 2008, 46(3):293-298.
167. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106(4):644-659. [quiz 60].
168. Hyams J.S., Griffiths A., Markowitz J., Baldassano R.N., Faubion W.A., Colletti R.B., et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012, 143(2):365-374. [e2].
169. Rosh J.R., Lerer T., Markowitz J., Goli S.R., Mamula P., Noe J.D., et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009, 104(12):3042-3049.
170. Russell R.K., Wilson M.L., Loganathan S., Bourke B., Kiparissi F., Mahdi G., et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33(8):946-953.
171. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130(2):323-333. [quiz 591].
172. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146(12):829-838.
173. de Ridder L., Escher J.C., Bouquet J., Schweizer J.J., Rings E.H., Tolboom J.J., et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004, 39(1):46-52.
174. Crandall W., Hyams J., Kugathasan S., Griffiths A., Zrubek J., Olson A., et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009, 49(2):183-190.
175. Teitelbaum J.E., Saeed S., Triantafyllopoulou M., Daum F. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr 2007, 44(2):279-282.
176. Afzal N.A., Shenoy M.U., Haque S., Wilcox D., Shah N. Recognition and treatment of genitourinary complications in paediatric Crohn's disease using infliximab. Acta Paediatr 2010, 99(7):1042-1046. [Oslo, Norway: 1992].
177. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340(18):1398-1405.
178. Panaccione R., Loftus E.V., Binion D., McHugh K., Alam S., Chen N., et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011, 25(8):419-425.
179. Dewint P., Hansen B.E., Verhey E., Oldenburg B., Hommes D.W., Pierik M., et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014, 63:292-299.
180. Hyams J., Walters T.D., Crandall W., Kugathasan S., Griffiths A., Blank M., et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011, 27(3):651-662.
181. Lamireau T., Cezard J.P., Dabadie A., Goulet O., Lachaux A., Turck D., et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004, 10(6):745-750.
182. Barrie A., Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(11):1424-1429.
183. Kugathasan S., Miranda A., Nocton J., Drolet B.A., Raasch C., Binion D.G. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003, 37(2):150-154.
184. Escher J.C., Stoof T.J., van Deventer S.J., van Furth A.M. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr 2002, 34(4):420-423.
185. Krishnan S., Banquet A., Newman L., Katta U., Patil A., Dozor A.J. Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics 2006, 117(4):1440-1443.
186. Silbermintz A., Krishnan S., Banquet A., Markowitz J. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr 2006, 42(3):324-326.
187. Carpenter E., Jackson M.A., Friesen C.A., Scarbrough M., Roberts C.C. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr 2004, 144(4):541-544.
188. Lichtenstein G.R., Bala M., Han C., DeWoody K., Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8(4):237-243.
189. DeBoer M.D., Barnes B.H., Stygles N.A., Sutphen J.L., Borowitz S.M. Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment. J Pediatr Gastroenterol Nutr 2012, 54(4):486-490.
190. Malik S., Ahmed S.F., Wilson M.L., Shah N., Loganathan S., Naik S., et al. The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn's disease (CD). J Crohns Colitis 2012, 6(3):337-344.
191. Ryan B.M., Russel M.G., Schurgers L., Wichers M., Sijbrandij J., Stockbrugger R.W., et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004, 20(8):851-857.
192. Franchimont N., Putzeys V., Collette J., Vermeire S., Rutgeerts P., De Vos M., et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004, 20(6):607-614.
193. Thayu M., Leonard M.B., Hyams J.S., Crandall W.V., Kugathasan S., Otley A.R., et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008, 6(12):1378-1384.
194. Miheller P., Kiss L.S., Lorinczy K., Lakatos P.L. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. Expert Opin Biol Ther 2012, 12(2):179-192.
195. Vande Casteele N., Compernolle G., Ballet V., Van Assche G., Gils A., Vermeire S., et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial. Gastroenterology 2012, 142(5):S211-S212.
196. Steenholdt C., Brynskov J., Thomsen O.O., Munck L.K., Fallingborg J., Christensen L.A., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014, 63:919-927.
197. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
198. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1):52-65.
199. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58(4):492-500.
200. Armuzzi A., Pugliese D., Danese S., Rizzo G., Felice C., Marzo M., et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013, 19(5):1065-1072.
201. Sprakes M.B., Ford A.C., Warren L., Greer D., Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012, 6(2):143-153.
202. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134(7):1861-1868.
203. Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013, 108(6):962-971.
204. Jones J., Kaplan G.G., Peyrin-Biroulet L., Baidoo L., Devlin S., Melmed G.Y., et al. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data. Gastroenterology 2013, 144(5):S179.
205. Kierkus J., Iwanczyk B., Wegner A., Dadalski M., Grzybowska-Chlebowczyk U., Lazowska I., et al. P525 Efficacy infliximab with immunomodulator and infliximab alone of maintenance therapy in children with Crohn's disease - multicenter randomized study. J Crohn's Colitis 2013, 7:S220-S221.
206. Cucchiara S., Escher J.C., Hildebrand H., Amil-Dias J., Stronati L., Ruemmele F.M. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?. J Pediatr Gastroenterol Nutr 2009, 48(3):257-267.
207. Feagan B.G., McDonald J.W., Panaccione R., Enns R.A., Bernstein C.N., Ponich T.P., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014, 146:681-688.
208. Reenaers C., Louis E., Belaiche J., Seidel L., Keshav S., Travis S. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?. Aliment Pharmacol Ther 2012, 36(11-12):1040-1048.
209. Kestens C., van Oijen M.G., Mulder C.L., van Bodegraven A.A., Dijkstra G., de Jong D., et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013, 11(7):826-831.
210. Hyams J.S., Lerer T., Griffiths A., Pfefferkorn M., Kugathasan S., Evans J., et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15(6):816-822.
211. Baert F., Noman M., Vermeire S., Van Assche G., DH G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348(7):601-608.
212. Miele E., Markowitz J.E., Mamula P., Baldassano R.N. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004, 38(5):502-508.
213. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cezard J.P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006, 118(1):11-19.
214. Lee L.Y., Sanderson J.D., Irving P.M. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012, 24(9):1078-1085.
215. Wewer V., Riis L., Vind I., Husby S., Munkholm P., Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006, 42(1):40-45.
216. de Ridder L., Rings E.H., Damen G.M., Kneepkens C.M., Schweizer J.J., Kokke F.T., et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008, 14(3):353-358.
217. Stephens M.C., Shepanski M.A., Mamula P., Markowitz J.E., Brown K.A., Baldassano R.N. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003, 98(1):104-111.
218. Jacobstein D.A., Markowitz J.E., Kirschner B.S., Ferry G., Cohen S.A., Gold B.D., et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005, 11(5):442-446.
219. Crandall W.V., Mackner L.M. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003, 17(1):75-84.
220. Friesen C.A., Calabro C., Christenson K., Carpenter E., Welchert E., Daniel J.F., et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004, 39(3):265-269.
221. Kugathasan S., Levy M.B., Saeian K., Vasilopoulos S., Kim J.P., Prajapati D., et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002, 97(6):1408-1414.
222. Lahdenne P., Wikstrom A.M., Aalto K., Kolho K.L. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res 2010, 62(6):785-790.
223. Kolho K.L., Ruuska T., Savilahti E. Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007, 96(1):128-130. [Oslo, Norway: 1992].
224. Hamalainen A., Lahdenne P., Wikstrom A., Aalto K., Kolho K.L. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid. Clin Exp Rheumatol 2012, 30(4):590-591.
225. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58(4):501-508.
226. de Bie C.I., Escher J.C., de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012, 18(5):985-1002.
227. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3(2):47-91.
228. Veereman-Wauters G., de Ridder L., Veres G., Kolacek S., Fell J., Malmborg P., et al. Risk of infection and prevention in pediatric patients with IBD. J Pediatr Gastroenterol Nutr 2012, 54(6):830-837.
229. Mackey A.C., Green L., Leptak C., Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48(3):386-388.
230. Parakkal D., Sifuentes H., Semer R., Ehrenpreis E.D. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011, 23(12):1150-1156.
231. Sokol H., Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009, 58(10):1427-1436.
232. Diak P., Siegel J., La Grenade L., Choi L., Lemery S., McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010, 62(8):2517-2524.
233. Kwon H.J., Cote T.R., Cuffe M.S., Kramer J.M., Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138(10):807-811.
234. Haddock R., Garrick V., Horrocks I., Russell R.K. A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab. J Crohns Colitis 2011, 5(6):623-627.
235. Hiremath G., Duffy L., Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011, 52(2):230-232.
236. De Bie C.I., Hummel T.Z., Kindermann A., Kokke F.T., Damen G.M., Kneepkens C.M., et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011, 33(2):243-250.
237. Katz L., Gisbert J.P., Manoogian B., Lin K., Steenholdt C., Mantzaris G.J., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18(11):2026-2033.
238. Kopylov U., Mantzaris G.J., Katsanos K.H., Reenaers C., Ellul P., Rahier J.F., et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011, 33(3):349-357.
239. Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13(9):1093-1099.
240. Sandborn W.J., Colombel J.F., Schreiber S., Plevy S.E., Pollack P.F., Robinson A.M., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17(1):141-151.
241. Pariente B., Pineton de Chambrun G., Krzysiek R., Desroches M., Louis G., De Cassan C., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18(7):1199-1206.
242. Ben-Horin S., Waterman M., Kopylov U., Yavzori M., Picard O., Fudim E., et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11(4):444-447.
243. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137(5):1628-1640.
244. Lazzerini M., Martelossi S., Magazzu G., Pellegrino S., Lucanto M.C., Barabino A., et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013, 310(20):2164-2173.
245. Felipez L.M., Gokhale R., Tierney M.P., Kirschner B.S. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr 2012, 54(1):28-33.
246. Lazzerini M., Martelossi S., Marchetti F., Scabar A., Bradaschia F., Ronfani L., et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007, 25(4):419-427.
247. Gisbert J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010, 16(5):881-895.
248. Griffiths A., Koletzko S., Sylvester F., Marcon M., Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr 1993, 17(2):186-192.
249. Cezard J.P., Munck A., Mouterde O., Morali A., Lenaerts C., Lachaux A., et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol 2009, 33(1 Pt 1):31-40.
250. Tolia V., Massoud N., Klotz U. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. J Pediatr Gastroenterol Nutr 1989, 8(3):333-338.
251. Christensen L.A., Fallingborg J., Jacobsen B.A., Abildgaard K., Rasmussen H.H., Rasmussen S.N., et al. Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. Dig Dis Sci 1993, 38(10):1831-1836.
252. Wiersma H., Escher J.C., Dilger K., Trenk D., Benninga M.A., van Boxtel C.J., et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10(5):626-631.
253. Wilschanski M., Sherman P., Pencharz P., Davis L., Corey M., Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996, 38(4):543-548.
254. Belli D.C., Seidman E., Bouthillier L., Weber A.M., Roy C.C., Pletincx M., et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988, 94(3):603-610.
255. Takagi S., Utsunomiya K., Kuriyama S., Yokoyama H., Takahashi S., Iwabuchi M., et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther 2006, 24(9):1333-1340.
256. Yamamoto T., Nakahigashi M., Umegae S., Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review. Eur J Gastroenterol Hepatol 2010, 22(1):1-8.
257. Turner D., Shah P.S., Steinhart A.H., Zlotkin S., Griffiths A.M. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011, 17(1):336-345.
258. Feagan B.G., Sandborn W.J., Mittmann U., Bar-Meir S., D'Haens G., Bradette M., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008, 299(14):1690-1697.
259. Rolfe V.E., Fortun P.J., Hawkey C.J., Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006, 4:Cd004826.
260. Renna S., Camma C., Modesto I., Cabibbo G., Scimeca D., Civitavecchia G., et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008, 135(5):1500-1509.
261. Blum E., Katz J.A. Postoperative therapy for Crohn's disease. Inflamm Bowel Dis 2009, 15(3):463-472.
262. Pascua M., Su C., Lewis J.D., Brensinger C., Lichtenstein G.R. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2008, 28(5):545-556.
263. Doherty G., Bennett G., Patil S., Cheifetz A., Moss A.C. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009, 4:Cd006873.
264. Peyrin-Biroulet L., Deltenre P., Ardizzone S., D'Haens G., Hanauer S.B., Herfarth H., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009, 104(8):2089-2096.
265. Gordon M., Naidoo K., Thomas A.G., Akobeng A.K. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011, 1:Cd008414.
266. Regueiro M., El-Hachem S., Kip K.E., Schraut W., Baidoo L., Watson A., et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. Dig Dis Sci 2011, 56(12):3610-3615.
267. De Cruz P.K.M., Hamilton A.L., Ritchie K.J., Krejany S., Gorelik A., Liew D., et al. Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. the POCER study. Gastroenterology 2013, 144(5):S164.
268. Doherty G.A., Bennett G.C., Cheifetz A.S., Moss A.C. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther 2010, 31(8):802-809.
269. Yamamoto T. Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. World J Gastroenterol 2010, 16(43):5405.
270. Vasseur F., Gower-Rousseau C., Vernier-Massouille G., Dupas J.L., Merle V., Merlin B., et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010, 105(8):1893-1900.
271. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H., Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133(2):412-422.
272. Kim P.S., Zlatanic J., Korelitz B.I., Gleim G.W. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999, 94(11):3254-3257.
273. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Tai R., Matuchansky C., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347(8996):215-219.
274. Mantzaris G.J., Roussos A., Christidou A., Koilakou S., Kalantzis C.N., Petraki K., et al. The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease. J Crohns Colitis 2007, 1(1):28-34.
275. Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7(1):80-85.
276. Clarke K., Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012, 18(1):174-179.
277. Fraser A.G., Morton D., McGovern D., Travis S., Jewell D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(4):693-697.
278. Olivieri I., D'Angelo S., Padula A., Leccese P., Nigro A., Palazzi C. Can we reduce the dosage of biologics in spondyloarthritis?. Autoimmun Rev 2013, 12(7):691-693.
279. Oussalah A., Chevaux J.B., Fay R., Sandborn W.J., Bigard M.A., Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010, 105(5):1142-1149.
280. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142(1):63-70. [e5; quiz e31].
281. Waugh A.W., Garg S., Matic K., Gramlich L., Wong C., Sadowski D.C., et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010, 32(9):1129-1134.